NewAmsterdam Pharma BV

The biggest upcoming catalysts for NewAmsterdam Pharma’s CETP inhibitor obicetrapib as a means for lowering low-density lipoprotein cholesterol (LDL-C) are regulatory submissions later this year based

When Michael Davidson, CEO of NewAmsterdam Pharma, describes his company’s lead asset obicetrapib, he frames it as a solution to one of cardiology’s most persistent challenges: managing residual cardi

Many public biopharmaceutical companies have taken advantage of the ongoing capital markets recovery in 2024 by raising money through follow-on public offerings (FOPOs) after announcing key research a

Cytokinetics Brought Down In the earlier halcyon days of biotech, the licensing of a biotech company’s lead drug to a big pharma partner would be associated with a substantial jump in the licensor’s